Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis
Peripheral arterial disease is one common vascular disease most caused by atherosclerosis. As with stroke and coronary heart disease, peripheral arterial disease is one clinical type of atherosclerotic cardiovascular disease with many unmeasured environmental and genetic components. MTHFR C677T polymorphism is associated with the increased risk of ischemic stroke and coronary heart disease. MTHFR C677T polymorphism is associated with decreasing enzyme activity and increasing homocysteine levels. Meta-analysis of studies had demonstrated an association between elevated plasma homocysteine levels and peripheral arterial disease. Elevated plasma homocysteine level is closely related to MTHFR C677T polymorphism. Recent studies had clarified the relationship of MTHFR C677T polymorphism and peripheral arterial disease. So we performed a meta-analysis to investigate the association between MTHFR C677T polymorphism and peripheral arterial disease. We searched the database PubMed, Embase, and Cochrane Library for all English-language articles related to peripheral arterial disease and MTHFR C677T through 30 June 2020. Analysis results were shown by forest plot. Publication bias was estimated using funnel plot. A total of 15 studies comprising 1929 patients with peripheral arterial disease and 2952 healthy controls were included in the meta-analysis. Significant associations between MTHFR C677T genetic polymorphism and peripheral arterial disease were found (OR = 1.31, 95% CI: 1.09–1.58, P <0.01). But there was no significant association (poor OR = 1.11, 95% CI: 0.98–1.26, P =0.11) between the T allele carrier and peripheral arterial disease. Our meta-analysis suggested that MTHFR C677T genetic polymorphism TT genotype may be associated with increased peripheral arterial disease risk. But further studies with large sample sizes are needed to confirm our findings.
To compare the efficacy of endovascular treatment for iliac vein compression syndrome (IVCS) with or without acute deep venous thrombosis of lower extremity. This study retrospectively analyzed the clinical data of 300 IVCS patients, who received endovascular treatment between January 2013 and December 2017. According to whether IVCS was complicated by deep venous thrombosis or not, these patients were divided into non-thrombotic iliac vein lesion group (NIVL group, n = 127) and post-thrombotic iliac vein lesion group (PIVL group, n = 173). After endovascular treatment, all patients were followed up to assess the symptoms improvement and to evaluate the patency of iliac vein. The technical success rate was 98% (294/300), and percutaneous transluminal angioplasty with stenting was adopted in 294 cases. The incidence of perioperative complications was 36.33% (109/300), but no severe complications occurred. During a mean follow-up of 22.3 months (range 6–30 months), 9(6.82%, 9/132) patients in PIVL group had recurrence of deep venous thrombosis, but nobody had deep venous thrombosis and varicose veins recurrence in NIVL group. The effective rate of endovascular treatment in NIVL group and PIVL group was 96.88% and 90.15% (P =0.050), while the cumulative primary patency of iliac vein in NIVL group was significantly higher than that in PIVL group (P =0.008). The endovascular treatment is an effective, feasible, safe method for treating IVCS. There is no difference in the efficacy of IVCS patients with or without deep venous thrombosis, but the medium and long-term patency of patients with deep venous thrombosis is lower than that in patients without deep venous thrombosis.
2 September 2025 in Phlebology: The Journal of Venous Disease
Objective: This study aims to investigate the incidence, risk factors, and clinical characteristics of deep vein thrombosis (DVT) following radiofrequency ablation (RFA) combined with sclerotherapy for varicose veins. Methods: A retrospective analysis was conducted on patients who underwent combined RFA and sclerotherapy between June 2018 and June 2024. The incidence of postoperative DVT and its clinical characteristics were evaluated, with 13 potential risk factors assessed through univariate and multivariate logistic regression. Patients with distal DVT were divided into two groups: Group A (treatment with prophylactic-dose anticoagulation) and Group B (no anticoagulation), with thrombus resolution outcomes compared between the groups. Results: Among 567 patients with varicose veins, including 226 males and 341 females (male-to-female ratio 1:1.51), with a mean age of 57.79 ± 11.38 years (range: 28–77 years), postoperative DVT occurred in 46 patients (8.11%), 36 of whom (78.26%) were diagnosed within 3 days. Thrombosis predominantly affected the muscular veins and posterior tibial veins (91.30%). Multivariate analysis identified a history of thrombosis, injection volume >10 mL of foam, and injection sites distal to the ankle joint as independent risk factors for DVT. Furthermore, Group A demonstrated a significantly lower prevalence of thrombosis at each time point compared to Group B ( p < .05). Conclusion: The incidence of postoperative DVT following combined RFA and foam sclerotherapy for varicose veins is relatively high, with the majority occurring in the early postoperative period. Thrombosis primarily affects the muscular and posterior tibial veins. A history of thrombosis, injection volume >10 mL of foam, and injection sites distal to the ankle joint are independent risk factors. Prophylactic-dose anticoagulation therapy may facilitate thrombus resolution in patients with distal DVT.
8 May 2025 in Phlebology: The Journal of Venous Disease
Objective: The incidence, risk factors, and clinical presentation of deep venous thrombosis (DVT) vary with age. This study aimed to evaluate the differences in clinical characteristics of DVT among patients of different ages. Methods: We retrospectively analyzed 938 patients with symptomatic lower extremity DVT admitted to our hospital between January 2020 and January 2024. Patients were categorized into youth (65 years) groups. Demographic data, comorbidities, risk factors, clinical presentations, and management approaches were collected and analyzed. Results: Most participants were middle-aged or elderly, with young patients constituting only 11.19% of the study population. The youth group had a slight female predominance, while the middle-aged and elderly group had a balanced gender distribution. The elderly group were more likely to have comorbidities such as diabetes and malignancies, though they had a lower prevalence of autoimmune diseases compared to younger patients. Congenital risk factors were relatively rare in the overall population, yet were present in 22.86% of young patients, a significantly higher proportion than in the middle-aged and elderly groups. Most patients with DVT were provoked, especially in the elderly group. The prevalence of concurrent congenital and acquired factors was 13.33% in the youth group, compared to only 4.97% in the middle-aged group and 2.88% in the elderly group. Proximal DVT was most frequent in middle-aged patients, while young patients were more likely to seek treatment in the acute phase and undergo surgical intervention. Anticoagulation noncompliance was noted in nearly 40% of elderly patients but only 6.67% of young patients. Conclusion: Risk factors and clinical characteristics of DVT vary significantly with age, particularly between young and elderly patients. Young patients were more inclined to seek prompt and effective treatment and demonstrated better adherence to anticoagulation therapy.
Introduction: This study aimed to evaluate the clinical efficacy of endovenous treatment (ET) via the profunda femoral vein (PFV) approach for iliofemoral venous obstruction with inadequate femoral vein (FV) inflow in patients with severe postthrombotic syndrome (PTS). Methods: A retrospective analysis included 32 patients who underwent this procedure between January 2021 and January 2023. Clinical symptoms were evaluated using the Villalta score and Venous Clinical Severity Score (VCSS) at baseline, 1 year, and 2 years. Patency rates were determined by duplex ultrasonography. Univariate logistic regression analysis was used to identify risk factors for in-stent restenosis (ISR). Results: The mean age of the patients was 65.5 ± 8.9 years, and 56.3% were men. Among 32 patients, technical success was achieved in all cases (100%). Postoperative in-stent thrombosis occurred in 18.8% (6/32) of patients. Kaplan–Meier analysis revealed primary patency rates of 100% ± 0%, 96.9% ± 3.1%, 93.8% ± 4.2%, 87.5% ± 5.9%, and 65.6% ± 8.4% at 1, 3, 6, 12, and 24 months, respectively. ISR developed in 11 patients, all of whom underwent reintervention, yielding a secondary patency rate of 87.5% ± 5.9% at 2 years. Baseline Villalta scores (17.4 ± 5.5) and VCSS (13.2 ± 2.5) significantly decreased to 6.5 ± 3.0 and 5.1 ± 1.8 at 2 years postoperatively (both p < 0.05). Anticoagulation noncompliance and history of iliofemoral deep vein thrombosis (DVT) were independent predictors of ISR. Conclusion: ET via the PFV approach is a safe and effective option for iliofemoral venous obstruction with inadequate FV inflow in severe PTS, providing favorable patency rates and significant symptom relief. Anticoagulation noncompliance and history of iliofemoral DVT are key factors for ISR.